AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is preparing to launch its pivotal Phase 3 program for its lead treatment-resistant ...

Atai Beckley Inc. (NASDAQ:ATAI) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 20, 2026, Canaccord analyst Sumant Kulkarni raised the price target on Atai Beckley Inc.

Event context and recent move in AtaiBeckley AtaiBeckley (ATAI) has been drawing attention after recent trading, with the stock last closing at US$4.02 and showing mixed short term performance, ...

View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Some of Wall Street’s biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...

Atai Life Sciences announced a financing deal to raise approximately $50 million by selling 18,264,840 ordinary shares and pre-funded warrants to purchase an additional 4,566,210 shares. The funds ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...

atai Life Sciences (NASDAQ:ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happened: The clinical-stage biotechnology company focused on ...

ATAI Life Sciences, a Peter Thiel-backed biopharmaceutical company developing psychedelic drugs to treat mental health, has taken a majority stake in U.S. firm Psyber. Psyber is a business that wants ...